Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VRTX stock price vs EW: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EW's multiple
Needs EW P/E.
Implied fair value · at VRTX's multiple
Needs VRTX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
11 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Edwards Lifesciences Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
VRTX vs AMGN
Gilead Sciences, Inc.
VRTX vs GILD
BIOGEN INC.
VRTX vs BIIB
Moderna, Inc.
VRTX vs MRNA
Illumina, Inc.
VRTX vs ILMN
ABBOTT LABORATORIES
VRTX vs ABT
JOHNSON & JOHNSON
VRTX vs JNJ
Medtronic plc
VRTX vs MDT
BOSTON SCIENTIFIC CORP
VRTX vs BSX
BAXTER INTERNATIONAL INC
VRTX vs BAX
DENTSPLY SIRONA Inc.
VRTX vs XRAY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe VRTX can sustain its superior margin structure and ROIC while closing some of the growth gap to EW, then VRTX looks attractive to own because the stock is priced at a lower P/E despite materially better profitability.
VRTX trades at 34.5x P/E versus EW at 51.6x, yet the valuation model implies $790.03 per share, or 49.6% upside from the current $528.04 price. The gap is consistent with VRTX’s stronger profitability profile and lower earnings multiple, while EW range and historical band suggest the current price is below a reasonable valuation corridor.
Supporting Metrics
